This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Abassi, Z. A. Articles by Keiser, H. R. Search for Related Content PubMed PubMed Citation Articles by Abassi, Z. A. Articles by Keiser, H. R. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB CYCLOSPORIN A

(Hypertension. 1996;27:1140-1148.)
© 1996 American Heart Association, Inc.

Articles

Effects of Cyclosporin A on the Synthesis, Excretion, and Metabolism of Endothelin in the Rat

Zaid A. Abassi; Federico Pieruzzi; Farid Nakhoul; Harry R. Keiser

From the Hypertension-Endocrine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Md, and Istituto di Clinica Medica e Terapia Medica, Universita' di Milano, and Centro di Fisiologia Clinica e Ipertensione, Ospedale Maggiore, Milan, Italy (F.P.).

Correspondence to Harry R. Keiser, MD, Hypertension-Endocrine Branch, National Heart, Lung, and Blood Institute, Building 10, Room 8C103, 10 Center Dr, MSC 1754, Bethesda, MD 20892-1754.

Abstract Increasing evidence suggests that endothelin, a potent vasoconstrictor, is implicated in cyclosporin A (CsA)–induced nephrotoxicity. Increased levels of urinary and circulating endothelin have been described in CsA-treated humans and animals. The exact mechanisms by which CsA induces these increases are still unknown, and no data indicate whether these elevated levels reflect increased synthesis or decreased clearance of endothelin. In the present study, we investigated the effects of CsA administration (50 mg/kg per day IP for 6 days) to rats on plasma and urinary levels of endothelin; expression of endothelin-1 (ET-1), ET-3, and endothelin-converting enzyme in renal tissue; clearance of infused ¹²⁵I–ET-1; and degradation of ¹²⁵I–ET-1 by recombinant neutral endopeptidase. Rats given CsA for 6 days developed severe renal insufficiency, as shown by a 74% decrease in creatinine clearance rate (Ccr) (P<.006). Ccr was remarkably improved in CsA-treated rats that received bosentan, the combined antagonist of both endothelin A and endothelin B receptors. Urinary excretion of endothelin increased from an undetectable level to 31.7±6.0 pg/24 h (P<.001), and plasma levels of endothelin were unchanged (2.8±0.2 to 3.1±0.2 pg/mL). Reverse transcription followed by quantitative polymerase chain reaction revealed that ET-1 mRNA in the renal medulla increased by 59% (P<.006), whereas the expression of both ET-3 and endothelin-converting enzyme was unchanged. In other rats, neither acute nor chronic treatment with CsA affected either the clearance of ¹²⁵I–ET-1 from the blood or the renal and pulmonary uptake of the peptide. Moreover, CsA did not affect the degradation of ¹²⁵I–ET-1 by highly purified recombinant neutral endopeptidase, a well-known endothelinase. Taken together, these data suggest that the elevated urinary endothelin levels obtained after CsA treatment originate from the kidney and reflect increased renal synthesis of ET-1. Moreover, the production of endothelin appears to be regulated at the mRNA transcription level, and expressions of ET-1 and ET-3 are regulated independently.

Key Words: endothelins • metabolic clearance rate • cyclosporine • endopeptidase

This article has been cited by other articles:

				D. Ramzy, L. C. Tumiati, E. Tepperman, R. Sheshgiri, J. Jackman, M. Badiwala, and V. Rao Dual immunosuppression enhances vasomotor injury: Interactive effect between endothelin-1 and nitric oxide bioavailability. J. Thorac. Cardiovasc. Surg., April 1, 2008; 135(4): 938 - 944. [Abstract] [Full Text] [PDF]

				D. Ramzy, V. Rao, L. C. Tumiati, N. Xu, S. Miriuka, D. Delgado, and H. J. Ross Role Of Endothelin-1 and Nitric Oxide Bioavailability in Transplant-Related Vascular Injury: Comparative Effects of Rapamycin and Cyclosporine Circulation, July 4, 2006; 114(1_suppl): I-214 - I-219. [Abstract] [Full Text] [PDF]

				S. Sano, S. Itami, and K. Yoshikawa Treatment of Primary Erythromelalgia with Cyclosporine N. Engl. J. Med., August 21, 2003; 349(8): 816 - 817. [Full Text] [PDF]

				D. Lucini, R. V. Milani, H. O. Ventura, M. R. Mehra, F. Messerli, and M. Pagani Study of Arterial and Autonomic Effects of Cyclosporine in Humans Hypertension, June 1, 2000; 35(6): 1258 - 1263. [Abstract] [Full Text] [PDF]

				Y. Takeda, I. Miyamori, K. Furukawa, S. Inaba, and H. Mabuchi Mechanisms of FK 506–Induced Hypertension in the Rat Hypertension, January 1, 1999; 33(1): 130 - 136. [Abstract] [Full Text] [PDF]

				T. J Rabelink, E. S.G Stroes, K.P. Bouter, and P. Morrison Endothelin blockers and renal protection: a new strategy to prevent end-organ damage in cardiovascular disease? Cardiovasc Res, September 1, 1998; 39(3): 543 - 549. [Full Text] [PDF]

				K. Okada, Y. Nishida, H. Murakami, I. Sugimoto, H. Kosaka, H. Morita, C. Yamashita, and M. Okada Role of Endogenous Endothelin in the Development of Graft Arteriosclerosis in Rat Cardiac Allografts : Antiproliferative Effects of Bosentan, a Nonselective Endothelin Receptor Antagonist Circulation, June 16, 1998; 97(23): 2346 - 2351. [Abstract] [Full Text] [PDF]